Downloads: 333
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pin.13007.pdf | 2.56 MB | Adobe PDF | View/Open |
Title: | A case of Langerhans cell sarcoma on the scalp: Whole‐exome sequencing reveals a role of ultraviolet in the pathogenesis |
Authors: | Katsuragawa, Hiroyuki Yamada, Yosuke https://orcid.org/0000-0001-7952-2706 (unconfirmed) Ishida, Yoshihiro Kaku, Yo Fujimoto, Masakazu https://orcid.org/0000-0002-0575-6507 (unconfirmed) Kataoka, Tatsuki R. Haga, Hironori |
Author's alias: | 桂川, 広幸 山田, 洋介 石田, 雄大 加来, 洋 藤本, 正数 片岡, 竜貴 羽賀, 博典 |
Keywords: | CDKN2A Langerhans cell histiocytosis Langerhans cell sarcoma MAPK pathway PD-L1 TP53 ultraviolet whole-exome sequencing |
Issue Date: | Nov-2020 |
Publisher: | Wiley-Blackwell |
Journal title: | Pathology International |
Volume: | 70 |
Issue: | 11 |
Start page: | 881 |
End page: | 887 |
Abstract: | Langerhans cell sarcoma (LCS) is a high‐grade neoplasm with overtly malignant cytological features and a Langerhans cell phenotype. The underlying genetic features are poorly understood, and only a few alterations, such as those of the MARK pathway‐related genes, CDKN2A and TP53 have been reported. Here we present a 70‐year‐old male with LCS on the scalp and pulmonary metastasis. The multinodular tumor, 3.0 cm in diameter, consisted of diffusely proliferated pleomorphic cells with numerous mitoses (53/10 HPFs). Immunohistochemically, the tumor cells were positive for CD1a, Langerin and PD‐L1, and the Ki‐67 labeling index was 50%. These pathological features were consistent with LCS, and were also observed in the metastatic tumor. Whole‐exome sequencing revealed that both the primary and metastatic tumors harbored a large number of mutations (>20 mutations/megabase), with deletion of CDKN2A and TP53 mutation, and highlighted that the mutational signature was predominantly characteristic of ultraviolet (UV) exposure (W = 0.828). Our results suggest, for the first time, that DNA damage by UV could accumulate in Langerhans cells and play a role in the pathogenesis of LCS. The high mutational burden and PD‐L1 expression in the tumor would provide a rationale for the use of immune checkpoint inhibitors for treatment of unresectable LCS. |
Rights: | This is the peer reviewed version of the following article: ['Pathology International', 70(11), 881-887], which has been published in final form at https://doi.org/10.1111/pin.13007. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. The full-text file will be made open to the public on 16 August 2021 in accordance with publisher's 'Terms and Conditions for Self-Archiving'. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 This is not the published version. Please cite only the published version. |
URI: | http://hdl.handle.net/2433/259188 |
DOI(Published Version): | 10.1111/pin.13007 |
PubMed ID: | 33410565 |
Appears in Collections: | Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.